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ABSTRACT
Background: We sought to determine the real-
world incidence of and risk factors for van-
comycin-associated acute kidney injury (V-AKI)
in hospitalized adults with acute bacterial skin
and skin structure infections (ABSSSI).
Methods: Retrospective, observational, cohort
study at ten U.S. medical centers between 2015
and 2019. Hospitalized patients treated with
vancomycin (C 72 h) for ABSSSI and C one
baseline AKI risk factor were eligible. Patients
with end-stage kidney disease, on renal
replacement therapy or AKI at baseline, were
excluded. The primary outcome was V-AKI by
the vancomycin guidelines criteria.
Results: In total, 415 patients were included.
V-AKI occurred in 39 (9.4%) patients. Indepen-
dent risk factors for V-AKI were: chronic alcohol
abuse (aOR 4.710, 95% CI 1.929–11.499), no
medical insurance (aOR 3.451, 95% CI
1.310–9.090), ICU residence (aOR 4.398, 95% CI
1.676–11.541), Gram-negative coverage (aOR
2.926, 95% CI 1.158–7.392) and vancomycin
duration (aOR 1.143, 95% CI 1.037–1.260).
Based on infection severity and comorbidities,
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34.7% of patients were candidates for oral
antibiotics at baseline and 39.3% had non-pu-
rulent cellulitis which could have been more
appropriately treated with a beta-lactam.
Patients with V-AKI had significantly longer
hospital lengths of stay (9 vs. 6 days, p = 0.001),
higher 30-day readmission rates (30.8 vs. 9.0%,
p\0.001) and increased all-cause 30-day mor-
tality (5.1 vs. 0.3%, p = 0.024)
Conclusions: V-AKI occurred in approximately
one in ten ABSSSI patients and may be largely
prevented by preferential use of oral antibiotics
whenever possible, using beta-lactams for non-
purulent cellulitis and limiting durations of
vancomycin therapy.
Keywords: Acute bacterial skin and soft tissue
infection; Acute kidney injury; Nephrotoxicity;
Vancomycin
Key Summary Points
In patients with at least one baseline risk
factor for acute kidney injury (AKI) treated
with vancomycin for acute bacterial skin
and skin structure infections,
vancomycin-associated acute kidney
injury (V-AKI) occurred in 9.4%.
Each additional day of vancomycin
therapy beyond day 3 increased the odds
of V-AKI by 14.3%.
The majority of patients in this study
could have been more appropriately
treated with safer alternatives.
V-AKI may be largely prevented by
preferential use of oral antibiotics
whenever possible, using beta-lactams for
non-purulent cellulitis and limiting
durations of vancomycin therapy.
INTRODUCTION
Acute bacterial skin and skin structure infec-
tions (ABSSSIs) are the most common infections
encountered in both the ambulatory and inpa-
tient settings [1–4]. In 2013, approximately 3.4
million individuals sought emergency depart-
ment care for ABSSSI in the United States [1].
Although rates have recently stabilized, this
figure represents a three-fold increase over two
decades earlier and has coincided with rising
hospital admission rates, secondary complica-
tions and healthcare resource utilization
[1, 5–7]. The increases in ABSSSI incidence and
severity have been linked to the emergence,
spread and persistence of community-acquired
methicillin-resistant Staphylococcus aureus (CA-
MRSA) as a predominant pathogen [7].
Although the prevalence of invasive MRSA
infections may be declining in some regions, it
remains a predominant pathogen among
patients with purulent ABSSSI in the US [8–11].
Vancomycin has been the standard therapy
for serious ABSSSI caused by resistant Gram-
positive bacteria for decades [9, 12]. It remains
the antibiotic most extensively studied in
ABSSSI randomized controlled clinical trials
(RCTs) with efficacy and safety outcomes gen-
erally similar to new comparators [13, 14].
Guidelines recommend vancomycin for first-
line treatment of ABSSSI due to suspected or
confirmed MRSA with the highest strength
recommendation [9, 15]. Despite this support
and its widespread use, recognition of van-
comycin’s shortcomings [poor tissue penetra-
tion, decreased activity against strains with
higher minimum inhibitory concentrations
(MICs) or the heteroresistant phenotype, need
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for therapeutic drug-monitoring and nephro-
toxicity] has led many experts to question its
future role in the treatment of ABSSSI
[13, 16, 17]. To counter concerns about reduced
effectiveness, experts have recommended more
intensive vancomycin dosing in serious infec-
tions, targeting serum trough concentration
levels between 15 and 20 mg/L as a surrogate for
area under the concentration–time curve
(AUC) C 400 [18, 19]. More aggressive van-
comycin dosing has been associated with
increased reports of vancomycin-associated
acute kidney injury (V-AKI) [19, 20]. On the
other hand, less intensive vancomycin dosing is
recommended for non-severe ABSSSI [15], and
these patients may be candidates for early
transition to oral therapy, attenuating van-
comycin exposure-associated renal injury. Fur-
thermore, RCTs comparing vancomycin to
other anti-MRSA agents for the treatment of
ABSSSI have documented low overall rates of
renal adverse events [13, 14]. There are a num-
ber of reasons to question whether the low rates
of V-AKI observed in ABSSSI RCTs can be gen-
eralized to the real-world setting. First, patients
with well-described risk factors for V-AKI were
either excluded or underrepresented in these
studies [13]. Antibiotics are administered for a
pre-specified duration, generally 7–14 days, and
in some RCTs there is the option to transition to
oral therapy around day 3 [21–24]. In the real-
world setting, patients have multiple risk fac-
tors, are frequently on concomitant nephro-
toxic medications, and intravenous (IV)
antibiotics are often continued long after
patients became candidates for oral therapy
[6, 19, 25, 26]. This is concerning, because some
studies have shown that the risk of V-AKI
increases with longer durations of therapy [19].
Finally, although a clear distinction can be
made between a patient presenting with
necrotizing fasciitis and a stable patient with an
uncomplicated abscess, the vast majority of
ABSSSIs fall within a gray area between these
entities, and clinicians may err on the side of
caution with a more intensive vancomycin
dosing schedule.
V-AKI is typically reversible; however, AKI
can further complicate a patient’s hospital
course and has been associated with prolonged
hospital and intensive care unit (ICU) lengths of
stay and increased overall mortality [19, 27–29].
Given the large number of patients treated with
vancomycin for ABSSSI, V-AKI in this group
would be expected to exert a tremendous bur-
den on the healthcare system. Recent studies
have demonstrated reduced rates of V-AKI when
vancomycin is dosed to target an AUC/MIC of
400–600, rather than trough-based dosing
[30, 31]. Perceived challenges with implemen-
tation of AUC-based monitoring (time alloca-
tion, training requirements, costs) may dissuade
its use in non-critically ill ABSSSI patients.
Newer agents with proven efficacy for MRSA
infections are also available, but are not rou-
tinely prescribed for ABSSSI because of higher
drug acquisition costs and/or relative lack of
experience compared to vancomycin.
These considerations underscore the need to
better characterize V-AKI with real-world use
among hospitalized patients treated with this
agent for ABSSSI. The objectives of this study
were therefore to (1) determine the incidence of
V-AKI with real-world use among hospitalized
patients with ABSSSI, (2) identify baseline and
treatment-related risk factors for V-AKI among
hospitalized ABSSSI patients, and (3) explore
antimicrobial stewardship opportunities to
improve appropriate vancomycin use in
ABSSSIs.
STUDY DESIGN
This was a multicenter, retrospective, observa-
tional, cohort study conducted from January
2015 to June 2019 at ten US medical centers
(seven academic urban and three academic
rural) representative of a diverse geographic
region and patient population. Approval was
obtained from each center’s institutional review
board (IRB) with a waiver for informed consent.
The Wayne State University IRB served as the
coordinating IRB. Potential patients were
screened from reports generated based on
International Classification of Diseases, 10th
Revision, Clinical Modification (ICD-10-CM)
diagnostic codes for ABSSSI. Patients were eli-
gible for the study if they met the following
criteria: (1) age C 18 years; (2) IV vancomycin
Infect Dis Ther
initiated B 24 h of admission and continued for
C 72 h; (3) ABSSSI per the US Food and Drug
Administration definition [32]; and (4) C one
baseline risk factor for AKI (Supplementary
Appendix 1) [27, 33–37]. Patients were excluded
if any of the following were true: (1) baseline
serum creatinine[4.0 mg/dL; (2) end-stage
renal disease or receipt of chronic or emergent
renal replacement therapy prior to vancomycin
initiation; (3) AKI at the time of vancomycin
initiation [38]; (4) concomitant infection
requiring systemic antimicrobial therapy when
vancomycin was initiated (patients with bac-
teremia thought to be from an ABSSSI source
were included); or (5) pregnant or nursing
mother. Relevant patient demographic, clinical,
treatment and outcome data were extracted
from the electronic medical record by study
investigators at each center and entered into a
secured electronic data collection form [39].
Patients were followed until hospital discharge.
Readmissions to the same institution within
30 days of discharge were also recorded. A con-
venience sample of 500 patients was targeted
based on feasibility and anticipated funding
including 200 patients from the lead investiga-
tor’s site and 30 patients each from ten addi-
tional medical centers. Due to early study
termination, the target sample size was not met.
Comorbidity burden was quantified by cal-
culating the Charlson Comorbidity score [40].
Immunosuppression was defined as previously
described [41]. The systemic inflammatory
response syndrome (SIRS), quick Sequential
Organ Failure Assessment (qSOFA) and severe
sepsis were evaluated according to consensus
guidelines using the worst physiological mea-
surements recorded within 24 h of vancomycin
initiation [37, 42]. The Dundee classification
was used to determine severity of illness at
infection onset [41, 43]. The Dundee classifica-
tion is a validated scoring system for ABSSSI
based on routinely measured objective physio-
logical parameters and the presence of comor-
bidities that may complicate or delay the
resolution of infection [41, 43]. Patients in class
I are candidates for oral antibiotic therapy tar-
geted to Streptococcus pyogenes and S. aureus.
Initial IV antibiotic therapy, targeted to these
Gram-positive pathogens is appropriate for
patients in classes II and III, while therapy
should be broadened to cover Gram-negative
and anaerobic bacteria for class IV [41, 43].
Initial serum creatinine was measured within
24 h of the first vancomycin dose. Peak serum
creatinine was the highest value recorded while
receiving vancomycin to within 72 h of dis-
continuation. Glomerular filtration rate (GFR)
was estimated using the Cockcroft–Gault Mod-
ification of Diet and Renal Disease (MDRD) and
Chronic Kidney Disease Epidemiology Collab-
oration (CKD-EPI) equations [36, 44, 45] Where
available, vancomycin exposure was evaluated
using initial steady-state trough concentrations
[19]. Vancomycin was dosed and monitored
according to each hospital’s standard of care.
The primary outcome was V-AKI evaluated
according to vancomycin guidelines definition
as an increase from baseline in serum creatinine
of C 0.5 mg/L or 50% on C two consecutive
measurements [18]. V-AKI was also evaluated
according to the RIFLE (risk, injury, failure, loss,
end-stage renal disease) and the Acute Kidney
Injury Network (AKIN) criteria. [46, 47] The risk
period was from vancomycin initiation to 72 h
after the last dose or at hospital discharge,
which ever occurred first [48].
Statistical Analysis
Descriptive statistics were used to characterize
the cohort. Continuous variables were reported
as medians (interquartile ranges, IQR), whereas
categorical variables were expressed as counts
and percentages. Bivariate associations between
covariates and V-AKI were expressed as odds
ratios and 95% confidence intervals (CIs).
To identify independent predictors of V-AKI,
we modeled both occurrence of V-AKI and time
to V-AKI. Occurrence of V-AKI was evaluated by
multivariable logistic regression. Covariates
with a p value less than 0.2 and with biological
plausibility by unadjusted analyses were entered
into the model through defined blocks starting
with baseline demographic and clinical vari-
ables followed by vancomycin-related variables
and other management-related variables. Step-
wise techniques were used to build a parsimo-
nious model with variables remaining in the
Infect Dis Ther
Table 1 Baseline patient and hospital characteristics and unadjusted odds ratios for vancomycin-associated acute kidney
injury
Characteristic n = 415
n (%) or median (IQR)
Odds ratio (95% conﬁdence interval) p value
Age, years 58 (46–69) 0.996 (0.976–1.016) 0.671
Age C 65 years 150 (36.1) 0.988 (0.497–1.965) 0.973
Sex
Male 217 (52.3) 1.711 (0.863–3.394) 0.121
Female 198 (47.7) Reference –
Actual body weight (kg) 91 (74–115) 1.004 (0.996–1.011) 0.323
Body mass index (kg/m2) 31 (25–39) 1.010 (0.986–1.034) 0.416
Obese (BMI C 30 kg/m2) 230 (55.4) 0.932 (0.481–1.807) 0.835
Baseline serum creatinine (mg/dL) 0.82 (0.70–1.00) 1.386 (0.521–3.685) 0.513
Baseline serum creatinine[ 1.5 mg/dL 13 (3.1) 0.798 (0.101–6.308) 1.000
Baseline estimated GFR
Cockroft Gault (mL/min) 98 (71–129) 1.002 (0.996–1.009) 0.486
CG\ 45 mL/min/1.73 m2 31 (7.5) 0.647 (0.148–2.920) 0.559
MDRD (mL/min/1.73 m2) 94 (74–114) 1.000 (0.990–1.009) 0.943
MDRD\ 45 mL/min/1.73 m2 19 (4.6) 1.141 (0.254–5.135) 0.863
CKD-EPI (mL/min/1.73 m2) 97 (78–117) 0.998 (0.986–1.009) 0.687
CKD-EPI\ 45 mL/min/1.73 m2 223 (5.5) 0.423 (0.056–3.230) 0.393
Race
Caucasian 192 (46.3) Reference –
African American 177 (42.7) 0.440 (0.203–0.953) 0.037
Othera 46 (11.1) 1.102 (0.412–2.885) 0.843
Hospital
A 193 (46.5) Reference –
B 58 (14) 1.026 (0.321–3.276) 0.966
C 30 (7.2) 2.769 (0.910–8.428) 0.073
D 2 (0.5) 0 1.0
E 30 (7.2) 0.477 (0.060–3.789) 0.484
F 4 (1.0) 0 1.0
G 30 (7.2) 0.989 (0.212–4.618) 0.989
H 16 (3.9) 4.615 (1.304–16.334) 0.018
I 22 (5.3) 2.186 (0.572–8.361) 0.253
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Table 1 continued
Characteristic n = 415 n (%) or
median (IQR)
Odds ratio (95% conﬁdence interval) p value
J 30 (7.2) 1.538 (0.411–5.753) 0.522
Medical insurance
Medicare 137 (33.0) Reference –
Medicaid 68 (16.4) 0.827 (0.279–2.450) 0.731
Private 129 (31.1) 0.875 (0.365–2.102) 0.766
Mixed 49 (11.8) 0.926 (0.284–3.019) 0.898
Uninsured 32 (7.7) 3.472 (1.283–9.396) 0.014
Admission source
Home 375 (90.4) Reference –
Nursing facility 27 (6.5) 0.753 (0.171–3.312) 0.708
Homeless 8 (1.9) 1.345 (0.161–11.244) 0.784
Other 5 (1.2) 0 1.00
Social history
Tobacco use 101 (24.3) 1.433 (0.697–2.946) 0.325
Alcohol abuse 39 (9.4) 4.126 (1.831–9.298) \ 0.001
IV drug abuse 38 (9.2) 1.529 (0.560–4.173) 0.405
Marijuana use 35 (8.4) 0.896 (0.261–3.072) 0.861
Comorbidities
Heart failure 61 (14.7) 1.573 (0.686–3.606) 0.281
Diabetes mellitus 152 (36.6) 1.736 (0.895–3.367) 0.100
COPD 70 (16.9) 1.816 (0.841–3.922) 0.124
Peripheral vascular disease 42 (10.1) 1.717 (0.674–4.375) 0.257
Chronic venous insufﬁciency 16 (3.9) 0.633 (0.081–4.928) 0.663
Cancer 48 (11.6) 0.862 (0.292–2.542) 0.788
Liver disease 24 (5.8) 0.404 (0.053–3.075) 0.366
Immunosuppression 22 (5.3) 0.445 (0.058–3.400) 0.423
Psychiatric disorder 65 (15.7) 1.714 (0.772–3.804) 0.181
Charlson Comorbidity score 1 (0–3) 1.141 (0.986–1.322) 0.077
Hospitalization within 90 days 92 (22.2) 1.880 (0.924–3.825 0.078
Infect Dis Ther
Table 2 Baseline infection and illness severity characteristics and unadjusted odds ratios for vancomycin-associated acute
kidney injury
Characteristic n = 415
n (%) or median
(IQR)
Odds ratio (95% conﬁdence
interval)
p value
Dundee class
Class 1 144 (34.7) Reference –
Class 2 69 (16.6) 0.529 (0.169–1.659) 0.275
Class 3 136 (32.8) 0.909 (0.416–1.988) 0.811
Class 4 66 (15.9) 1.020 (0.395–2.635) 0.967
ABSSSI type
Non-purulent cellulitis 163 (39.3) Reference –
Purulent cellulitis 99 (23.9) 1.296 (0.546–3.079) 0.556
Cutaneous abscess 92 (22.2) 1.099 (0.438–2.758) 0.841
Wound infection 61 (14.7) 1.742 (0.684–4.435) 0.245
ABSSSI location
Upper extremity 60 (14.5) Reference
Lower extremity 248 (59.8) 1.100 (0.432–2.796) 0.842
Torso 57 (13.7) 0.327 (0.063–1.694) 0.183
Buttock/perianal 24 (5.8) 0.818 (0.153–4.370) 0.814
Head/neck 26 (6.3) 0.750 (0.141–3.988) 0.736
Blood culture obtained 293 (70.6) 2.014 (0.864–4.697) 0.099
Positive blood culture 20 (4.8) 1.075 (0.240–4.816) 0.925
Failed outpatient therapy for index ABSSSI 94 (22.4) 1.195 (0.559–2.551) 0.646
Abnormal temperature ([ 38 C or\ 36 C) 96 (23.1) 1.163 (0.545–2.481) 0.696
Respiratory rate C 22 breath/minute 76 (18.3) 0.795 (0.321–1.970) 0.619
Heart rate[ 90 beats/minute 262 (63.1) 1.350 (0.663–2.750) 0.407
Systolic blood pressure B 100 mmHg 87 (21.0) 0.970 (0.429–2.194) 0.942
Abnormal WBC ([ 12 9 103 or\ 4 x 103) 200 (48.2) 0.815 (0.419–1.584) 0.546
Altered mental status (GCS\ 15) 20 (4.8) 2.571(0.815–8.115) 0.096
qSOFA C 2 41 (9.9) 1.389 (0.511–3.774) 0.518
C 2 SIRS criteria present 202 (48.7) 1.122 (0.580–2.170) 0.732
Severe sepsis/septic shock 13 (3.1) 1.794 (0.383–8.401) 0.452
ICU admission within 24 h of hospital
admission
30 (7.2) 4.152 (1.708–10.097) 0.001
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final model if the adjusted p value was\ 0.05.
Multi-collinearity was assessed via the variance
inflation factor, with values\3 being consid-
ered acceptable. Effect modification was also
evaluated. To examine time to V-AKI, we
employed Cox proportional hazards regression.
Patients who did not experience V-AKI were
censored 72 h after the last dose of vancomycin
or at hospital discharge, which ever occurred
first.
Two sensitivity analyses were performed: (1)
excluding cases enrolled from the Detroit
Medical Center which was our largest contrib-
utor, and (2) excluding sites that contributed
less than ten cases.
All calculations were performed with SAS 9.4
Statistical Software (SAS Institute, Cary, NC,
USA) and SPSS, v.25 (IBM. Armonk, NY, USA).
RESULTS
A total of 415 patients met inclusion criteria
and were evaluated, representing 57,143 van-
comycin-days. Demographic, clinical and
infection characteristics are shown in Tables 1
and 2. The median age was 58 (46–69) years and
approximately half (52.3%) were male. Both
Caucasian and African American patients were
well represented (46.3% and 42.7%, respec-
tively). The majority of patients (55.4%) were
obese. Diabetes mellitus (36.6%), chronic
obstructive pulmonary disease (16.9%) and
psychiatric illnesses (15.7%) were the most
common comorbidities. The median GFR at
initial evaluation ranged from 94 (71–129) mL/
min/1.73 m2 (MDRD) to 98 (71–129) mL/min
(Cockroft–Gault) with few patients (4.6–7.5%)
Table 2 continued
Characteristic n = 415 n (%) or
median (IQR)
Odds ratio (95% conﬁdence
interval)
p value
Mechanical ventilation within 24 h of
admission
7 (1.7) 4.011 (0.752–21.397) 0.080
Skin/tissue/ﬂuid specimen obtainedb 195 (77.4) 0.348 (0.150–0.809) 0.014
Staphylococcus aureusb 102 (40.5)
MSSAb 33 (13.1)
MRSAb 69 (27.4)
Streptococcus spp.b 35 (13.9)
Gram-negativeb 30 (11.9)
Escherichia coli 7 (2.8)
Klebsiella pneumonia 6 (2.4)
Pseudomonas aeruginosa 4 (1.6)
No organisms/normal ﬂorab,c 41 (16.3)
ABSSSI acute bacterial skin and skin structure infection, BMI body mass index, C Celsius, CG Cockroft–Gault, CKD-EPI
chronic kidney disease epidemiology collaboration, CT computed tomography, GCS Glasgow Coma Scale, ICU intensive
care unit, MDRD Modiﬁcation of Diet in Renal Disease, MSSA methicillin-sensitive S. aureus, MRSA methicillin-resistant
S. aureus, MRI magnetic resonance imaging, OR operating room, SIRS systemic inﬂammatory response syndrome, qSOFA
quick Sequential Organ Failure Assessment, WBC white blood cell count
a Latino n = 20, Asian n = 3, Unknown n = 23
b n = 252 excluding patients with non-purulent cellulitis from whom a culture could not be obtained
c Normal ﬂora as per local laboratory deﬁnitions
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having a GFR under 45 mL/min. Nearly half
(48.7%) of patients meet criteria for sepsis but
few patients (3.1%) had severe sepsis at initial
evaluation. With regards to the Dundee classi-
fication for infection severity, 144 (34.7%) were
in severity class I, 69 (16.6%) in class II, 136
(32.8%) in class III and 66 (15.9%) in class IV.
The most common ABSSSI type and location
were non-purulent cellulitis (39.3%) and lower
extremity (59.8%), respectively.
ABSSSI management is summarized in
Table 3. Among patients from whom a tissue or
fluid specimen could potentially be obtained
(i.e., purulent cellulitis, abscess and wound
infection, n = 252), a culture was collected in
77.4%. S. aureus was the most frequently cul-
tured bacterial species (MSSA 13.1% and MRSA
27.4%). Twelve percent of cultures were positive
for Gram-negative bacteria. Overall, blood cul-
tures were collected from 70.6% of patients.
Blood cultures were obtained more frequently
as Dundee class increased from I to IV (59.7%,
55.1%, 78.7%, 93.9%; p\0.001 for trend).
Approximately 5% of the cohort had secondary
bacteremia (MSSA 1.2% and MRSA 2.9%).
Infectious disease services were consulted in
57.8% of cases, radiological testing was per-
formed in 57.8% and a source control procedure
was performed in 41.9%. No interactions
between these variables and Dundee class were
observed.
With regards to vancomycin therapy, the
median daily dose was 26 (17–31) mg/kg. Daily
doses[ 4000 mg were uncommon (4.1%) and
loading doses were used in 11.3%. The median
duration of vancomycin was 5 (4–6) days.
Vancomycin was administered for greater than
7 days to 20.7% of patients. In the subgroup of
patients that had a skin specimen culture col-
lected (n = 195), the length of vancomycin
therapy [5 (4–6) vs. 5 (4–7), p = 0.888] and the
proportion of patients that received[ 7 days of
vancomycin (18.8% vs 20.6%, p = 0.765), was
similar in patients with and without an MRSA
positive culture, respectively.
In total, 257 (61.9%) patients had at least
one steady-state vancomycin trough measured;
the median initial trough was 12.0 (8.4–16.0)
mg/L and 68.5% of patients had an initial
trough\15 mg/L. Concomitant antibiotics
with Gram-negative activity and/or antipseu-
domonal activity were used for  72 h in 59.8%
and 42.9% of patients, respectively. The use of
concomitant nephrotoxic medicines was also
common (61.9%) and 23.4% of patients
received parenteral contrast dye.
V-AKI according to the vancomycin con-
sensus guidelines, the RIFLE and AKIN criteria,
developed in 39 (9.4%), 50 (12.0%) and 64
(15.4%) patients, respectively (Table 4). The
median time to V-AKI onset was 4 (3–6) days.
Amongst patients who experienced V-AKI,
vancomycin was discontinued due to V-AKI in
26 (61.5%). V-AKI resolution occurred before or
at the time of discharge in 26 (61.5%) patients.
Resolution was not associated with vancomycin
discontinuation; resolution occurred in 65.4%
who continued vancomycin compared to 53.8%
who discontinued vancomycin due to V-AKI
(p = 0.485). Nephrology was consulted in 13
(3.1%) patients with V-AKI and emergent
hemodialysis was initiated in 4 (1.0%).
Bivariate associations between baseline
demographic, clinical and infection variables
and V-AKI are shown in Tables 1 and 2. No
medical insurance, chronic alcohol abuse and
ICU admission within 24 h of vancomycin ini-
tiation were positively associated with V-AKI,
while African American race was protective
(p\ 0.05). Notably, in our cohort, there was no
significant association between V-AKI and age,
obesity, or baseline GFR. With regards to van-
comycin-related variables (Table 3), receipt of
higher doses, including doses[4000 mg/day
and loading doses, were not associated with an
increased odds of V-AKI. Measurement of at
least one vancomycin trough level was associ-
ated with an increased risk of V-AKI (p = 0.043).
Although the number of patients with a
trough[20 mg/L was small (n = 25),
supratherapeutic troughs were associated with
increased V-AKI (OR 4.035, 95% CI
1.297–12.555). Longer durations of vancomycin
therapy were associated with increased risk
particularly among the approximately 20% of
patients who received vancomycin for[ 7 days
(OR 2.364, 95% CI 1.171–4.775). The receipt of
parenteral contrast dye or at least one con-
comitant nephrotoxic medication for C 48 h
was associated with a greater than two-fold
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Table 3 Management-related variables and unadjusted odds ratios for vancomycin-associated acute kidney injury
n = 415
n (%) or median
(IQR)
Odds ratio (95% conﬁdence
interval)
P value
Radiological test performed 240 (57.8) 1.514 (0.755–3.038) 0.240
X-ray 100 (24.1)
CT-scan 101 (24.3)
Ultrasound 66 (15.9)
MRI 34 (8.2)
Surgical consult 255 (61.4) 1.461 (0.718–2.973) 0.294
Dermatology consult 8 (1.9) 0.979 (0.964–0.993) 1.000
Infectious diseases consult 240 (57.8) 1.514 (0.755–3.038) 0.240
Source control procedure 174 (41.9) 0.960 (0.491–1.876) 0.905
Bedside incision and drainage 62 (14.9)
OR incision and drainage 100 (24.1)
Debridement 10 (2.4)
Amputation 5 (1.2)
Concomitant antipseudomonal
antibiotic C 72 h
178 (42.9) 2.603 (1.311–5.168) 0.006
Cefepime 84 (20.2) 1.407 (0.657–3.016) 0.380
Piperacillin-tazobactam 83 (20.0) 2.831 (1.411–5.681) 0.003
Receipt of IV contrast dye 97 (23.4) 2.241 (1.124–4.468) 0.019
Concomitant nephrotoxic drug C 48 h 257 (61.9) 2.572 (1.151–5.748) 0.021
Piperacillin-tazobactam 86 (20.7) 2.685 (1.340–5.379) 0.005
Vasopressors 2 (0.5) 9.868 (0.605–160.960) 0.179
Loop diuretic 81 (19.5) 1.977 (0.954–4.097) 0.063
ACE-inhibitor 64 (15.4) 1.224 (0.515–2.908) 0.646
Angiotensin receptor blocker 25 (6.0) 0.830 (0.188–3.659) 1.000
Tenofovir disoproxil fumarate 4 (1.0) 3.272 (0.332–32.234) 0.327
Non-steroidal anti-inﬂammatory 79 (19.0) 0.600 (0.227–1.587) 0.299
Acyclovir 5 (1.2) 6.721 (1.088–41.513) 0.018
ACE angiotensin converting enzyme, IV intravenous; operating room
a n = 257
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increased odds of V-AKI (Table 3). The use of
concomitant Gram-negative coverage (C 72 h)
was associated with an even higher odds of
V-AKI (OR 4.119, 95% CI 1.685–10.065).
Baseline variables independently associated
with the occurrence of V-AKI in the multivari-
able logistic regression analysis were (Table 5):
no medical insurance (aOR 3.451, 95%
1.310–9.090), chronic alcohol abuse (aOR
4.710, 95% CI 1.929–11.499) and ICU admis-
sion within the first 24 h of vancomycin ther-
apy (aOR 4.398, 95% 1.676–11.541). After
controlling for these variables, receipt of Gram-
negative coverage (aOR 2.926, 95% CI
1.158–7.392) and vancomycin duration (aOR
1.143, 95% 1.037–1.260) were positive predic-
tors of V-AKI.
The Cox proportional hazard model identi-
fied the following baseline variables signifi-
cantly associated with V-AKI (Table 6): no
medical insurance (aHR 2.898, 95% CI
1.303–6.445), chronic alcohol abuse (aHR
3.295, 95% CI 1.559–6.964), chronic pulmonary
disease (aHR 2.151, 95% CI 1.027–4.503) and
ICU admission within 24 h of vancomycin ini-
tiation (aHR 3.327, 95% CI 1.487–7.446). After
controlling for these variables, the only treat-
ment-related variable independently associated
with V-AKI was receipt of concomitant Gram-
negative coverage (aHR 2.812, 95% CI
1.160–6.817).
We performed exploratory analyses to better
understand the relationship between chronic
alcohol abuse, no medical insurance and V-AKI.
First, in patients with chronic alcohol abuse, the
presence of most comorbid conditions was not
higher with the exception of chronic liver dis-
ease (4.5 vs. 17.9%; p = 0.001) but there was no
interaction between liver disease and alcohol
abuse for V-AKI. Baseline serum creatinine, GFR
and the presence of sepsis were similar. We did
not discover differences in vancomycin dosing
nor was there evidence of differential van-
comycin exposure based on trough levels or
Table 5 Final logistic regression model for the occurrence of vancomycin-associated acute kidney injury
Parameter Adjusted odds ratio
(95% conﬁdence interval)
p value
No medical insurance 3.451 (1.310–9.090) 0.012
Chronic alcohol abuse 4.710 (1.929–11.499) 0.001
ICU admission within 24 h of vancomycin initiation 4.398 (1.676–11.541) 0.003
Receipt of Gram-negative coverage 2.926 (1.158–7.392) 0.023
Vancomycin durationa 1.143 (1.037–1.260) 0.007
AUC area under the curve, ICU intensive care unit
Overall p value (likelihood ration test) was\ 0.001; Hosmer–Lemeshow test p = 0.340; AUC 0.776 (95% CI
0.700–0.851)
a The adjusted odds ratio for vancomycin duration reﬂects the increased likelihood of V-AKI for each one day increase in
vancomycin length of therapy
Table 4 Vancomycin-associated acute kidney injury
Deﬁnition n = 415
n (%)
Consensus Guidelines deﬁnition 39 (9.4)
RIFLE 50 (12.0)
Risk 32 (7.7)
Injury 10 (2.4)
Failure 8 (1.9)
AKIN 64 (15.4)
Stage 1 47 (11.3)
Stage 2 10 (2.4)
Stage 3 7 (1.7)
AKIN acute kidney injury network, RIFLE risk, injury,
failure, loss of function, end-stage renal diseases
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vancomycin duration. We did however find
that blood cultures were collected more often in
these patients (68.9 vs. 87.2%; p = 0.017) and
concomitant piperacillin-tazobactam was given
to a higher proportion of patients with chronic
alcohol abuse (18.4 vs. 35.9%; p = 0.009).
Chronic alcohol abuse and concomitant piper-
acillin-tazobactam appeared to act synergisti-
cally to increase V-AKI risk: among patients who
did not receive piperacillin-tazobactam,
patients with chronic alcohol abuse was asso-
ciated with an increased odds of V-AKI,
although the association was not statistically
significant (OR 2.733, 95% CI 0.856–8.731) but
the association of chronic alcohol abuse and
V-AKI was more pronounced in those who also
received piperacillin-tazobactam (OR 5.00, 95%
CI 1.405–17.793). Gram-negative bacteria were
isolated in a similar proportion of patients
without and with chronic alcohol abuse (15.9
vs. 10.5%; p = 0.743). Next, with regards to
uninsured patients, when compared to patients
with some form of medical insurance, unin-
sured patients were significantly younger [59
(47–70) years vs. 51 (39–60) year;, p = 0.027],
had higher GFR by the Cockroft–Gault equation
[95 (68–129) mL/min vs. 118 (89–154) mL/min;
p = 0.016] and achieved lower vancomycin
trough levels [12 (9–17) mg/L vs. 8 (6–10) mg/L;
p\0.001]. Conversely, uninsured patients were
more likely to receive a concomitant nephro-
toxic drug (59.5 vs 78.1%; p = 0.038), in par-
ticular piperacillin-tazobactam (16.4 vs.
62.5%;p\0.001). However, the association
between no medical insurance and V-AKI was
qualitatively similar in those who did and did
not receive a concomitant nephrotoxic drug
(OR 3.466, 95% CI 1.309–9.177 and OR 3.063,
95% CI 0.328–28.577, respectively).
As shown in Table 1, rates of V-AKI varied
widely across centers. Sensitivity analyses
demonstrated that the final multivariable
logistic regression model had similar discrimi-
nation and satisfactory calibration when
patients enrolled from the Detroit Medical
Center (n = 193) were excluded as well as when
patients enrolled from sites that contributed
less than ten cases were excluded (Supplemen-
tary Appendix 2).
With regards to other important patient
outcomes, length of stay was significantly
longer in patients who experienced V-AKI [9
(6–3) days vs. 6 (5–9) days; p = 0.001] and a
significantly higher proportion of patients who
experienced V-AKI were readmitted to the hos-
pital within 30 days of discharge (30.8 vs. 9.0%;
p\0.001). Thirty-day all-cause mortality
occurred in three patients: one (0.3%) in the
non V-AKI group compared to two (5.1%) in the
V-AKI group (p = 0.024).
DISCUSSION
Vancomycin is the most commonly prescribed
antibiotic in US hospitals with recent studies
finding approximately one in four patients
receive vancomycin during the course of their
hospital stay [49]. Among pharmacists,
nephrologists and infectious diseases physi-
cians, there is a broad range of beliefs about
vancomycin’s propensity to cause V-AKI [50].
Previous studies have reported V-AKI rates
Table 6 Final Cox proportional hazards model for time to occurrence of vancomycin-associated acute kidney injury
Parameter Adjusted hazard ratio (95% conﬁdence interval) p value
No medical insurance 2.898 (1.303–6.445) 0.009
Chronic alcohol abuse 3.295 (1.559–6.964) 0.002
Chronic pulmonary disease 2.151 (1.027–4.503) 0.042
ICU admission within 24 h of vancomycin initiation 3.327 (1.487–7.446) 0.003
Receipt of Gram-negative coverage 2.812 (1.160–6.817) 0.022
ICU intensive care unit
The ﬁnal log likelihood ratio was–202.24. All covariates were dichotomized. The overall p value was\ 0.001
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ranging from less than 5% to greater than 40%
and a wide variety of risk factors have been
implicated [19, 33]. We conducted a focused
analysis of this adverse effect specifically in
hospitalized patients treated with vancomycin
for ABSSSI. Our study sample was enriched with
patients at higher risk of V-AKI because these
patients have been poorly represented in recent
randomized controlled ABSSSI studies. We
believe our cohort is more broadly representa-
tive of real-world ABSSSI patients managed in
the inpatient setting. We found that nearly one
in ten patients experienced V-AKI. This repre-
sents a two- to three-fold increase over recent
studies conducted for regulatory approval of
new antibiotics that used vancomycin as the
comparator and enrolled patients at low base-
line risk [22–24]. Consistent with previous
studies [19, 27], we found that patients who
experienced V-AKI had significantly longer
hospital lengths of stay, higher 30-day read-
mission rates and higher all-cause 30-day mor-
tality. Although we are cautious not to ascribe
causation, it is clear that patients who experi-
ence V-AKI place a significant burden on the
healthcare system. In our study, the median
length of stay of those who experienced V-AKI
was 3 days longer than those who did not,
which could translate into incremental costs to
the hospital for room and board alone of
approximately US$8000 depending on the
geographic location and type of institution [51].
Additional costs are incurred for pharmacist’s
time, laboratory monitoring, nephrology con-
sult (required in 3.1% of our cohort) and dial-
ysis (1.0% of our cohort). These findings
underscore the need to better understand the
individual patient- and drug-related risk factors
that would enable clinicians to safely and
effectively use vancomycin when it is indicated.
Some, but not all, previous studies have
found increased rates of V-AKI with higher
vancomycin trough levels [19, 27, 48]. In our
cohort, higher initial troughs within the thera-
peutic range (\ 20 mg/mL) were not positively
associated with V-AKI. Supratherapeutic levels
dramatically increased risk; however, few
patients had trough levels above 20 mg/L
resulting in imprecise estimates. Vancomycin is
predominantly eliminated in the urine by
glomerular filtration, therefore a decrease in
renal function, from any etiology, will increase
vancomycin serum concentrations [19, 50]. In
addition, changes in serum creatinine are
known to lag actual renal injury. This makes it
difficult to establish an exposure–nephrotoxic-
ity relationship. Aware of this, we restricted our
analysis to initial trough levels which may
explain the absence of an association for levels
of 15–20 mg/L compared to other studies that
have included levels collected throughout the
course of therapy [19, 33].
Unlike previous studies, we also did not
observe a positive relationship between van-
comycin dose and V-AKI [33, 52]. However, less
than 5% of patients received doses exceeding
4000 mg/day and the median daily dose
(26 mg/kg) was less than the standard 30 mg/
kg/day (15 mg/kg every 12 h). Loading doses
were also uncommon (11.4%). The majority of
our patients were obese. Other studies have
found obesity to be a significant risk factor for
V-AKI [18, 52]. Cognizant of this association,
clinicians may have under-dosed heavier
patients, minimizing our ability to detect a
relationship between higher doses or obesity
and V-AKI. The observation that patients who
received vancomycin therapeutic drug moni-
toring (TDM) was associated with over a two-
fold increased odds of V-AKI also suggests that
clinicians were more inclined to monitor van-
comycin therapy in individuals perceived to be
at higher risk or perhaps when longer durations
of therapy were planned. The fact that TDM did
not entirely obviate this risk attests to limita-
tions of trough level monitoring and under-
scores the need to minimize vancomycin use
when safer alternatives are suitable, particularly
in patients known to be at risk for V-AKI due to
concomitant nephrotoxic medications and/or
other risk factors.
Prior studies have found a significant asso-
ciation between longer vancomycin treatment
durations and risk for developing V-AKI
[18, 27, 53]. We found that each additional day
of therapy beyond 72 h was independently
associated with 14% increased odds of V-AKI,
and that durations greater that 7 days conferred
a greater than two-fold increased odds on uni-
variate analysis. There is now overwhelming
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data supporting short-course therapy in patients
with a variety of acute bacterial infections
including hospitalized patients [54, 55]. Our
study demonstrates the need to translate this
data into current clinical practice to minimize
iatrogenic harms of antibiotic therapy.
We found that novel risk factors, such as the
absence of medical insurance and chronic
alcohol abuse, were associated with V-AKI in
our cohort. Liver disease was more prevalent
among patients with chronic alcohol abuse and,
even though baseline serum creatinine and GFR
were similar in when stratified by chronic
alcohol abuse and liver disease, patients with
advanced liver disease may have renal impair-
ment that is substantially more severe than
suggested by serum creatinine concentration
[56]. We found that concomitant nephrotoxic
drugs, in particular piperacillin-tazobactam,
were used more frequently in those with alco-
hol abuse and uninsured patients; however, this
did not fully explain the increased V-AKI risk.
This, coupled with the observation that blood
cultures were collected more often in patients
with chronic alcohol abuse, implies that the
clinical picture may have suggested a more
severe or complicated infection despite the fact
that there was no difference in the objective
signs we collected. These novel findings under-
score the need to better characterize the epi-
demiology of ABSSSI in these vulnerable patient
populations so that effective and safe manage-
ment strategies can be developed.
One of the most important findings of this
study was that IV vancomycin was not indi-
cated in a large number of enrolled patients.
Nearly 40% of patients had non-purulent cel-
lulitis for which the predominant pathogen
remains beta-hemolytic streptococcus, even in
the post-CA-MRSA era [57, 58]. Narrow spec-
trum beta-lactams, which are not nephrotoxic
(except for rare cases of interstitial nephritis)
[59], are the drugs of choice for these infections
[15]. In addition, over one-third of patients
were candidates for upfront oral therapy based
on meeting Dundee class I criteria. Provider
perception that infections require IV antibiotics
is a common reason for hospital admission in
patients with ABSSSI. We now have a number of
well-tolerated oral antibiotics with high oral
bioavailability and appropriate spectrums of
activity to treat ABSSSI [60–64]. Interventions
targeted to stopping the continued overuse of
parenteral antibiotics in the inpatient setting
are needed.
Nearly 60% of patients in this study received
combination therapy with a Gram-negative
active antibiotic, yet only 16% of patients
exhibited the high-risk features for which it is
indicated (Dundee class IV). Exposing patients
to antibiotics with an unnecessarily broad-
spectrum of activity is unacceptable in the cur-
rent era of escalating antimicrobial resistance
and the increasing incidence and severity of
Clostridiodes difficile-associated diarrhea [65]. In
addition, receipt of Gram-negative coverage was
strongly and independently associated with
V-AKI. Mounting evidence suggests that the
combination of vancomycin and piperacillin-
tazobactam is associated with increases in
serum creatinine [35, 66]. Although our sample
size was not large enough to permit meaningful
exploration, the risk in our study did not appear
to be restricted to concomitant use of piper-
acillin-tazobactam only.
Our study has several important limitations.
First, the study design was retrospective and
observational and is therefore subject to the risk
of bias inherent in this design. However, in-
depth chart reviews allowed us to obtain
detailed patient-level data and include variables
that have not been assessed before. Next, we
only enrolled patients treated with vancomycin
and did not include a control group. As
observed in this study, patients treated with
vancomycin frequently have comorbidities and
baseline organ impairment and are exposed to
other agents which can be harmful to the kid-
neys, therefore we were not able to evaluate the
attributable risk from vancomycin itself. How-
ever, our study reflects real-world practice since
hospitalized patients often receive concomitant
nephrotoxins and have multiple comorbidities.
Our study was terminated early because of the
sponsor’s financial status and we did not enroll
our target sample size. Nearly half of the cohort
were enrolled from one medical center, limiting
generalizability. We observed wide ranges of
V-AKI across sites with outliers often being sites
that enrolled fewer patients. For these reasons,
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we conducted sensitivity analyses and found
the results of multivariable analyses to be
broadly consistent across sites. Antibiotic
developers often fund valuable real-world
research, and there is a desperate need for
alternative payment models to sustain antibi-
otic development and related research.
CONCLUSION
In conclusion, we found that nearly 10% of
hospitalized ABSSSI patients treated with van-
comycin experienced V-AKI. This adverse effect
exerts a tremendous burden on the patients and
the healthcare system and is largely pre-
ventable with three key changes in practice: (1)
use oral antibiotics whenever appropriate, (2)
treat non-purulent cellulitis with beta-lactams,
and (3) when vancomycin must be used for
ABSSSI, limit the duration of therapy to the
absolute minimum.
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